Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.43% $41.97
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 703.74 mill |
EPS: | -2.92 |
P/E: | -14.37 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 64.42 mill |
Avg Daily Volume: | 0.958 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -14.37 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.44x |
Company: PE -14.37 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-5.08 (-112.11%) $-47.05 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 39.20 - 44.61 ( +/- 6.46%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Jimenez Freddy A. | Buy | 20 000 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Buy | 4 166 | Common Stock |
2024-02-13 | Jimenez Freddy A. | Sell | 4 166 | Incentive Stock Option (Right to Buy) |
2024-02-13 | Jimenez Freddy A. | Sell | 20 000 | Incentive Stock Option (Right to Buy) |
2024-01-02 | Martin Samuel Bates | Buy | 10 750 | Common Stock |
INSIDER POWER |
---|
74.77 |
Last 97 transactions |
Buy: 2 900 849 | Sell: 507 801 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $41.97 (0.43% ) |
Volume | 0.510 mill |
Avg. Vol. | 0.958 mill |
% of Avg. Vol | 53.25 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $37.40 | N/A | Active |
---|
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.